Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).

Trial Details

NCT ID
NCT06596915
Phase
PHASE1
Sponsor
Shandong Boan Biotechnology Co., Ltd
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • BA1302
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. Metastatic or unresectable solid malignancy that is histologically or cytologically confirmed. Patients who have progressed on or after standar…
  • Part A: Advanced malignant solid tumors;
  • Part B: Metastatic melanoma, Advanced breast cancer, Advanced Non-small cell lung cancer (NSCLC), Advanced pancreatic adenocarcinoma.
  • Participants should be able to provide adequate tumor tissue for biomarker analysis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →